Metoprolol Retard 1a Farma

Metoprolol Tartrate, the active ingredient in Metoprolol Retard 1a Farma, is a beta‑adrenergic blocker presented as a tablet for oral use. It is used to manage high blood pressure, relieve angina, and improve outcomes in heart failure and post‑myocardial infarction patients.

GNH USA supplies Metoprolol Retard 1a Farma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Metoprolol Tartrate is employed in cardiovascular therapy to control blood pressure and reduce cardiac workload.

- Hypertension: lowers systolic and diastolic pressure, decreasing the risk of stroke and organ damage. - Angina pectoris: reduces myocardial oxygen demand, alleviating chest pain during exertion. - Chronic heart failure: improves ventricular function and reduces hospitalisation rates. - Post‑myocardial infarction prophylaxis: decreases the likelihood of recurrent cardiac events and mortality.

Metoprolol Tartrate may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Fatigue or tiredness - Dizziness, especially on standing - Cold extremities or reduced peripheral circulation - Gastrointestinal upset such as nausea or abdominal discomfort - Mild bradycardia (slow heart rate) - Sleep disturbances or vivid dreams

Serious or Rare Side Effects: - Severe bradycardia or heart block - Acute heart failure exacerbation - Bronchospasm in patients with asthma or COPD - Hypotensive crisis with syncope - Depression or mood changes - Allergic reactions including rash, angioedema, or anaphylaxis

Before initiating therapy, clinicians should assess individual risk factors and monitor patients regularly.

- Cardiovascular assessment: evaluate baseline heart rate, blood pressure, and cardiac function. - Respiratory conditions: avoid in uncontrolled asthma or severe chronic obstructive pulmonary disease. - Diabetes management: monitor blood glucose as β‑blockers may mask hypoglycaemia symptoms. - Concomitant drugs: review for potential interactions, especially with other rate‑controlling agents. - Pregnancy and lactation: use only if clearly needed after risk‑benefit evaluation. - Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture and direct sunlight.

Metoprolol Tartrate can influence, and be influenced by, several co‑administered medicines.

Major Interactions (Avoid): - Non‑selective β‑blockers: additive bradycardia and hypotension. - Calcium channel blockers (verapamil, diltiazem): profound AV‑node suppression. - Antidiabetic agents: may mask hypoglycaemia signs.

Moderate Interactions (Monitor Closely): - CYP2D6 inhibitors (e.g., fluoxetine, quinidine): increase metoprolol plasma levels. - NSAIDs: may reduce antihypertensive efficacy. - Antidepressants (tricyclics, MAO‑inhibitors): potential for enhanced cardiac depression.